Investigation of the use of molecular targeted drugs for ovarian cancer and the impact of companion testing on HBOC treatment in Chugoku and Shikoku regions

DOI
  • Tanaka Tamaki
    Department of Obstetrics and Gynecology, Kawasaki Medical School Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine
  • Saito Wataru
    Department of Obstetrics and Gynecology, Kawasaki Medical School
  • Shimoya Koichiro
    Department of Obstetrics and Gynecology, Kawasaki Medical School
  • Hibino Yumi
    Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center
  • Matsuoka Hirofumi
    Department of Obstetrics and Gynecology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
  • Arakaki Ryosuke
    Department of Obstetrics and Gynecology, Tokushima University
  • Yorimitsu Masae
    Department of Obstetrics and Gynecology, Hiroshima City Hiroshima Citizens Hospital
  • Sueoka Kotaro
    Department of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine
  • Aoe Hisashi
    Department of Obstetrics and Gynecology, Fukuyama City Hospital
  • Hirabayashi Kei
    Department of Obstetrics and Gynecology, JCHO Tokuyama Central Hospital
  • Ujihara Yusuke
    Department of Obstetrics and Gynecology, Kochi Medical School Hospital
  • Koh Iemasa
    Department of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University
  • Maekawa Masahiko
    Department of Obstetrics and Gynecology, Tokushima Prefectural Central Hospital
  • Yamamoto Yorito
    Department of Obstetrics and Gynecology, Kochi Health Sciences Center
  • Shiroyama Yuko
    Department of Obstetrics and Gynecology, Hiroshima Prefectural Hospital
  • Nakamura Hiroko
    Department of Obstetrics and Gynecology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center
  • Hayata Yu
    Department of Obstetrics and Gynecology, Kagawa Prefectural Central Hospital
  • Ito Hironori
    Department of Obstetrics and Gynecology, National Hospital Organization Iwakuni Clinical Center
  • Haruma Tomoko
    Department of Obstetrics and Gynecology, Okayama Saiseikai General Hospital
  • Fujita Shiho
    Department of Obstetrics and Gynecology, National Hospital Organization Fukuyama Medical Center
  • Ishikawa Masako
    Department of Obstetrics and Gynecology, Shimane University Faculty of Medicine
  • Narai Yoko
    Department of Obstetrics and Gynecology, Shimane Prefectural Central Hospital
  • Komatsu Hiroaki
    Department of Obstetrics and Gynecology, Faculty of Medicine Tottori University
  • Oishi Tetsuro
    Department of Obstetrics and Gynecology, Matsue City Hospital
  • Urabe Rie
    Department of Obstetrics and Gynecology, Chugoku Rosai Hospital
  • Shimamura Katsunori
    Department of Obstetrics and Gynecology, Saiseikai Shimonoseki General Hospital
  • Nonaka Michiko
    Department of Obstetrics and Gynecology, Tottori Prefectural Central Hospital
  • Tanaka Norifumi
    Department of Obstetrics and Gynecology, National Hospital Organization HigashiHiroshima Medical Center
  • Shimizu Miyuki
    Department of Obstetrics and Gynecology, Kagawa Rosai Hospital
  • Hongo Atsushi
    Department of Obstetrics and Gynecology, Kawasaki Medical School

Bibliographic Information

Other Title
  • 中国・四国地方における卵巣癌に対する分子標的治療薬の使用状況およびコンパニオン検査が与えるHBOC診療への影響の調査

Search this article

Abstract

<p>Synopsis: In this study, we analyzed how the molecular-targeted drugs and related companion diagnosis system were selected in patients newly diagnosis or recurrent ovarian cancer treated at the participating institution in Chugoku and Shikoku region between January 1, 2021 and December 31, 2021.</p><p>For newly diagnosed patients, PAOLA-1 regimen (combining maintenance olaparib and bevacizumab) was the most frequently used for HRD (58%), whereas for HRP cases, 55% were treated with bevacizumab and 45% with niraparib. Bevacizumab and niraparib were also used for patients who had not undergone companion diagnosis.</p><p>Recurrent cases were divided according to the presence or absence of platinum sensitivity. PARP inhibitors were used in 80% of platinum sensitive relapses, while the majority (78%) of the resistant cases were treated with bevacizumab.</p><p>Genetic counseling or testing was performed in 25 of 27 patients with tumor BRCA variant identified by HRD testing. It was revealed that most of the facilities which participated in this research have performed genetic intervention for patients with somatic variant identified by HRD testing, which could be an inducement for HBOC treatment.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top